First-line immunotherapy in advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an International Expert Panel Meeting by the Italian Association of Thoracic Oncology-Reference-Cited by-同舟云学术

First-line immunotherapy in advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an International Expert Panel Meeting by the Italian Association of Thoracic Oncology

Published:2022-02 Issue:1 Volume:7 Page:100355
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Gridelli C.,Peters S.,Mok T.,Forde P.M.,Reck M.,Attili I.,de Marinis F.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference47 articles.

1. Evaluation of Chemotherpeutic Agents;Karnofsky,1949

2. Toxicity and response criteria of the Eastern Cooperative Oncology Group;Oken;Am J Clin Oncol,1982

3. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience;Albain;J Clin Oncol,1991

4. Prognostic factors for patients with advanced non-small cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation;Takigawa;Lung Cancer,1996

5. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a phase II trial in patients with metastatic nonsmall cell lung carcinoma;Sweeney;Cancer,2001

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adjuvant (chemo)radiotherapy for patients with head and neck cancer: can comorbidity risk scores predict outcome?;Strahlentherapie und Onkologie;2024-09-02

2. Toxicity in the era of immune checkpoint inhibitor therapy;Frontiers in Immunology;2024-08-23

3. Pembrolizumab in Patients with Advanced Urothelial Carcinoma with ECOG Performance Status 2: A Real-World Study from the ARON-2 Project;Targeted Oncology;2024-08-06

4. Predictors of survival in immunotherapy‐based treatments in advanced melanoma: a meta‐analysis;International Journal of Dermatology;2024-08-04

5. Immune Checkpoint Inhibitors for Pediatric Cancers: Is It Still a Stalemate?;Pharmaceuticals;2024-07-26